Metraipolis › archive › dc_7fc6370d46a1
Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene… — Europe PMC PMID:41132654
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41132654
- DOI
- 10.3389/fimmu.2025.1667249
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T12:22:18.078Z
- SHA-256 of the archived text
ca751143dc80dc9fda441e746fb9d29c687e4e70dc716d3fefdcaf9dde88d694- Stable URL of this page
https://metraipolis.com/documento/dc_7fc6370d46a1
How to cite
Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene… — Europe PMC PMID:41132654 — Europe PMC (en), https://europepmc.org/article/MED/41132654 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7fc6370d46a1 (Metraipolis archive dc_7fc6370d46a1, sha256 ca751143dc80dc9fda441e746fb9d29c687e4e70dc716d3fefdcaf9dde88d694)
BibTeX
@misc{dc7fc6370d46a1,
title = {Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene… — Europe PMC PMID:41132654},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41132654},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7fc6370d46a1; sha256 ca751143dc80dc9fda441e746fb9d29c687e4e70dc716d3fefdcaf9dde88d694},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41132654. Agents can read the archived copy with the MCP tool read_document.